Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system

Advanced prostate cancer is treated by androgen ablation and/or androgen receptor (AR) antagonists. In order to investigate the mechanisms relevant to the development of therapy-resistant tumours, we established a new tumour model which closely resembles the situation in patients who receive androge...

Descripción completa

Detalles Bibliográficos
Autores principales: Culig, Z, Hoffmann, J, Erdel, M, Eder, I E, Hobisch, A, Hittmair, A, Bartsch, G, Utermann, G, Schneider, M R, Parczyk, K, Klocker, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362859/
https://www.ncbi.nlm.nih.gov/pubmed/10496349
http://dx.doi.org/10.1038/sj.bjc.6690684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362859/
https://www.ncbi.nlm.nih.gov/pubmed/10496349
http://dx.doi.org/10.1038/sj.bjc.6690684

Ejemplares similares